Dalton Pharma Services has entered into a manufacturing services agreement with Zafgen, Inc. to provide cGMP aseptic fill/finish services and analytical support for Zafgen’s lead obesity treatment.

“Adding Zafgen to our growing list of strategic relationships with innovative pharmaceutical clients is an important milestone for Dalton,” said Peter Pekos, Dalton Pharma’s president and chief executive officer. “We are thrilled to be working with the Zafgen team and look forward to a successful collaboration as we advance this breakthrough obesity therapy through clinical development.”

Thomas Hughes, chief executive officer of Zafgen, said, “The alliance with Dalton is a key part of our success in quickly advancing our first-in-class therapy for severe obesity into the next phase of clinical development. As a virtual company, Zafgen benefits tremendously from having the facilities and technical expertise found at Dalton. The opportunity to partner with a company that provides all aspects of manufacturing including the drug product and analytical services fits perfectly with Zafgen’s capital-efficient business model.”